|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Candesartan#Drug Interactions]] |
| {{Candesartan}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| | |
| Because candesartan is not significantly metabolized by the cytochrome P450 system and at therapeutic concentrations has no effects on P450 enzymes, interactions with drugs that inhibit or are metabolized by those enzymes would not be expected.
| |
| | |
| ===Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)===
| |
| | |
| In patients who are elderly, volume-depleted (including those on [[diuretic]]therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with [[angiotensin]]II receptor antagonists, including candesartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving candesartan and NSAID therapy.
| |
| | |
| The antihypertensive effect of [[angiotensin]]II receptor antagonists, including candesartan may be attenuated by NSAIDs including selective COX-2 inhibitors.
| |
| | |
| ===Lithium===
| |
| | |
| Reversible increases in serum [[lithium]]concentrations and toxicity have been reported during concomitant administration of [[lithium]]with ACE inhibitors, and with some [[angiotensin]]II receptor antagonists. An increase in serum [[lithium]]concentration has been reported during concomitant administration of [[lithium]]with ATACAND. Monitor serum [[lithium]]levels.
| |
| | |
| ===Dual Blockade of the Renin-angiotensin System (RAS)===
| |
| | |
| Dual blockade of the RAS with [[angiotensin]]receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of [[hypotension]], [[hyperkalemia]], and changes in renal function (including acute renal failure) compared to monotherapy. Closely monitor blood pressure, renal function and electrolytes in patients on ATACAND and other agents that affect the RAS.
| |
| | |
| Do not co-administer aliskiren with ATACAND in patients with diabetes. Avoid use of aliskiren with ATACAND in patients with renal impairment (GFR <60 ml/min) [seeCONTRAINDICATIONS (4)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ATACAND (CANDESARTAN CILEXETIL) TABLET [ASTRAZENECA LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a73e1339-9643-4eea-2cbe-e879c88fb50e | publisher = | date = | accessdate = 20 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{[[angiotensin]]II receptor antagonists}}
| |
| | |
| [[Category:[[angiotensin]]II receptor antagonists]]
| |
| [[Category:Tetrazoles]]
| |
| [[Category:Benzimidazoles]]
| |
| [[Category:Ethers]]
| |
| [[Category:Carboxylic acids]]
| |
| [[Category:Biphenyls]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |